$NOVO B (+0,59 %)
$LLY (+0,29 %)
$HIMS (+0,58 %)

Judge blocked $LLY (+0,29 %) Motion for summary speedy judgment in TIRZEPATID case

Case likely to continue for another six weeks

$HIMS (+0,58 %) 🚀

Evaluation $HIMS (+0,58 %) / $LLY (+0,29 %)

More interesting charts:

$LLY (+0,29 %)

Pharmaceutical giant Eli Lilly falls short of analysts' expectations. The company falls short of its forecasts. The share reacts significantly.

Eli Lilly announced on Tuesday that it expects sales of around USD 13.5 billion for the fourth quarter of 2024. The analysts' consensus estimate was USD 13.95 billion. The pharmaceutical giant thus fell short of expectations.

In particular, Eli Lilly expects sales of the popular obesity drug Zepbound and the related diabetes drug Mounjaro to fall short of expectations in the fourth quarter. For 2025, however, the company is forecasting sales that are largely above estimates.

The company announced that it expects fourth-quarter sales of $3.5 billion for Mounjaro and $1.9 billion for Zepbound. Analysts, on the other hand, had expected sales of 5.35 billion US dollars for Mounjaro and 2.08 billion US dollars for Zepbound, according to data collected by LSEG.

"Our previous forecast had predicted even faster growth in the quarter. In addition, lower than expected year-end channel inventories led to our fourth quarter results," said CEO David Ricks.

This was clearly punished by the shareholders. In an initial reaction, the share price fell by up to 8 percent.

"Although the market for blood glucose-regulating hormones and drugs in the US grew by 45 percent compared to the same quarter last year, our earlier guidance for the quarter had anticipated even faster growth. In addition, lower than expected year-end channel inventories contributed to our fourth quarter results," said CEO David Ricks.

The sales forecast for the fourth quarter of 2024 corresponds to year-on-year growth of 45%.

Sales of around USD 45.0 billion are expected for the 2024 financial year, while the consensus forecast is USD 45.55 billion.

Eli Lilly had already missed consensus expectations in the third quarter and revised its forecast for 2024 downwards.

For 2025, the company expects sales in the range of USD 58 to 61 billion, compared to consensus estimates of USD 58.48 billion.

Eli Lilly plans to release its financial results and guidance for the coming years on February 6, 2025.

Author: Krischan Orth, wallstreetONLINE Editorial Team

https://www.wallstreet-online.de/nachricht/18894264-anteilsscheine-fallen-eli-lilly-enttaeuscht-prognose-aktie-tiefenrausch

Eli Lilly
$LLY (+0,29 %)-CEO David Ricks stated that the company expects its experimental weight loss pill will be approved early next year, reports Bloomberg.

The drug could be a major breakthrough in the growing market for weight-control therapies.

Graphic: Bloomberg

After $LLY (+0,29 %) lost 7% today due to a weaker Q4 sales forecast, the share price fell slightly for $NOVO B (+0,59 %) also fell somewhat

Eli Lilly $LLY (+0,29 %) is in advanced negotiations negotiationsto acquire the cancer research specialized biotech company Scorpion Therapeutics which specializes in cancer research.

According to the Financial Times the deal is said to be worth up to 2.5 billion US dollars have.

Graphic: Bloomberg

Hello everyone,

I have been saving for almost three years now with the $XDWD (+0,14 %) and have a portfolio of just under 17k.

In the coming year, I would like to invest a large sum x in individual shares with a view to the long term.

The shares will be held until I retire and will not be used to speculate on short-term gains.

I have selected the following shares:

$TSLA (+0,78 %)

$NVDA (+4,83 %)

$MSFT (+1,02 %)

$SYK (-0,47 %)

$LLY (+0,29 %)

$AAPL (-0,67 %)

$RHM (+1,17 %)

$AMZN (+0,69 %)

The shares are not spectacular, but are market leaders and big names in their sector. However, this is of course no guarantee of a promising future.

What do you think of these shares, even if they may seem boring?

The US 🇺🇸 American FDA has Eli Lilly's
$LLY (+0,29 %) weight loss drug Zepbound for the treatment of patients with sleep apnea, CNBC reports.

Graphic: REUTERS/Mike Segar

$HIMS (+0,58 %) currently sells Compounted Semaglutide, which is still on the FDA shortlist, only Tirzepatide ($LLY (+0,29 %) GLP-1) was removed from the FDA shortage list yesterday!

However, HIMS is already planning to sell Compounded Liraglutide (a generic drug that is 100% legal to manufacture even without shortage) in 2025, which is just beginning, and thus become independent of Lilly and $NOVO B (+0,59 %) and

But: HIMS does not sell branded GLP-1 and offers semaglutide in a compounded version, which is considered the second best drug. Liraglutide, which HIMS could also offer, is off-patent but works significantly worse (only 12% weight loss compared to 15% for semaglutide). Tirzepatide is considered the best drug by Lilly.

Have 30% of my Net Worth in Hims, and have set the next limit buy at 20€, would love some Getquin Coins! ;)

The data on the new dietary supplement CagriSema, successor to the current drug Semaglutide, disappointed investors.

Over a 68-week period, patients lost an average of 22,7 percent of their body weight. In comparison, the old drug Semaglutide achieved a weight loss of 14,9 percent on average under the same conditions.

The new drug is therefore significantly more effective, but the share price was still penalized by over 27% at its peak, as 25% weight loss expected was expected.

The problem is that CagriSema is just as good as the competing product from Eli Lilly but is significantly more complex in the production and therefore expensive.

Subjective opinion: However, the patents on the current drug do not expire until the 2030s and this drug has not been a complete failure. It will therefore put a slight strain on Novo Nordisk's margin due to competitive pressure, but does not justify such a sell-off. I therefore took advantage of this crash and bought some shares for €80, as Novo is still well positioned overall. Let's see where the further journey takes us!

$NOVO B (+0,59 %) , $LLY (+0,29 %)